London, United Kingdom, Monday 6 September 2004. New data from the first international prospective study of statin treatment in people with the metabolic syndrome demonstrate that CRESTOR TM ...
The new cholesterol-lowering drug Crestor has more potentially harmful side effects than similar drugs and should be taken off the market, according to a lengthy correspondence published in today's ...
Washington, DC - A letter in the correspondence section of the June 24, 2004 issue of the Lancet has called for the removal of rosuvastatin (Crestor ®, AstraZeneca) from the market. "The renal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results